Latest Medicinal Cannabis Market News

ECS Botanics has achieved a milestone with direct-to-consumer sales exceeding 60% of total revenue, driven by the launch of innovative sugar-free THC gummies and a strategic distribution partnership.

Bioxyne Limited is expanding its footprint with a new UK GMP-certified medicinal cannabis manufacturing site, backed by £850,000 in funding from South of Scotland Enterprise. This move positions the company to tap into the UK’s growing medicinal cannabis market, the second largest in Europe.

Wellnex Life reported an 18.2% sales decline in Q1 FY26 amid delayed IP licensing revenue and increased costs, while securing new debt facilities and exiting the medicinal cannabis segment.

Cann Group Limited reported a 34% rise in dried flower production and doubled Botanitech brand flower sales in FY25, while cutting operating expenses by 35%. The company is targeting an EBITDA-positive FY26 amid ongoing debt restructuring.

Cann Group Limited reported a significant 56% reduction in net loss for FY25, driven by cost cuts and strong growth in dried flower sales, even as revenue declined due to shifting product preferences. The company faces going concern challenges but is actively pursuing debt refinancing and operational improvements.

Vitura Health reported modest revenue growth but a robust 23.5% increase in EBITDA for FY2025, fueled by key acquisitions and expanding telehealth services. Despite margin pressures in medicinal cannabis, the company’s strategic reset under new leadership sets the stage for further growth.

Althea Group Holdings announces the immediate resignation of founder and CEO Joshua Fegan, appointing Barry Katzman as interim CEO to steer the company’s THC beverage growth in North America.

Little Green Pharma reported a robust June 2025 quarter with record cash receipts and expanding European footprint, highlighted by a new production capacity in Denmark and the launch of its CherryCo brand in Germany.

ECS Botanics has launched the globally acclaimed Terphogz™ cannabis strains, including The Original Z™, into the Australian medicinal market, marking a strategic expansion of its premium product portfolio.

Cann Group Limited has resolved its legal dispute with Rua Biosciences, paving the way for new commercial agreements to supply medicinal cannabis products across Australia and New Zealand.

Little Green Pharma Ltd has reported a robust turnaround for FY2025, posting a $3.3 million profit after tax on revenues up 43%, driven by strong growth in Australia and Europe and strategic acquisitions.

Cann Group Limited has reported a strong operational update, exceeding its medicinal cannabis production targets and significantly reducing costs, while expanding sales channels and securing fresh capital to bolster its balance sheet.